BOULDER, Colo., May 10, 2017 (GLOBE NEWSWIRE) -- Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced first quarter 2017 financial results and provided a corporate update.
“It has been an exciting and productive first quarter of 2017, with encouraging business developments and clinical progress to report,” said William S. Marshall, Ph.D., president and chief executive officer of miRagen Therapeutics. “We continue to be encouraged by the interim results from our MRG-106 and MRG-201 Phase 1 clinical trials, and plan to provide updated clinical data at scientific conferences throughout the year. We also completed a merger to become a public company and concurrent financing during the quarter. With a cash runway through 2018, we believe we are well-positioned to deliver clinical data from our existing trials, expand these trials, and provide additional data that may broaden the potential clinical applications of our lead programs.”
“It has been an exciting and productive first quarter of 2017, with encouraging business developments and clinical progress to report,” said William S. Marshall, Ph.D., president and chief executive officer of miRagen Therapeutics. “We continue to be encouraged by the interim results from our MRG-106 and MRG-201 Phase 1 clinical trials, and plan to provide updated clinical data at scientific conferences throughout the year. We also completed a merger to become a public company and concurrent financing during the quarter. With a cash runway through 2018, we believe we are well-positioned to deliver clinical data from our existing trials, expand these trials, and provide additional data that may broaden the potential clinical applications of our lead programs.”
